Pembrolizumab in hemodialysis patients. Is it safe?
Nefrologia (Engl Ed). 2020 Nov-Dec;40(6):678-679.
doi: 10.1016/j.nefro.2019.11.007.
Epub 2020 Apr 27.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Nefrología, Hospital Universitario de Guadalajara, Guadalajara, España. Electronic address: [email protected].
- 2 Servicio de Nefrología, Hospital Universitario de Guadalajara, Guadalajara, España.
- 3 Servicio de Nefrología, Hospital Universitario de Guadalajara, Guadalajara, España; Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá de Henares (UAH), Alcalá de Henares, Madrid, España.
No abstract available
MeSH terms
-
Adenocarcinoma, Clear Cell / drug therapy*
-
Adenocarcinoma, Clear Cell / secondary
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antineoplastic Agents, Immunological / adverse effects*
-
B7-H1 Antigen / metabolism
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary
-
Glomerulonephritis, IGA / therapy
-
Graft Rejection / immunology
-
Humans
-
Kidney Transplantation
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Peritoneal Dialysis
-
Reoperation
-
Ribs*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
pembrolizumab